CD2-HM122-100μg / 询价
CD2-HM122-100μg x 5 / 询价
CD2-HM122-100μg x 10 / 询价
- 客服电话
- 技术支持
Human CD20 Protein-VLP
Recombinant Human CD20 Protein-VLP is expressed from HEK293.It contains Met1-Pro297 [Accession | P11836-1].
The target protein has a predicted MW of 34.3 kDa.
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Supplied as 0.22μm filtered solution in PBS, 300mM L-Arginine (pH 7.4). Notice: If you need it for immunization, water-soluble adjuvant is recommended.
Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
The purity of Human CD20 VLP is greater than 95% as determined by SEC-HPLC.
Immobilized Human CD20 VLP at 5μg/ml (100μl/Well) on plate on the plate. Dose response curve for Rituximab, hFc Tag with the EC50 of 11.4ng/ml determined by ELISA (QC Test).
Immobilized Human CD20 VLP at 5μg/ml (100μl/Well) on plate on the plate. Dose response curve for Ofatumumab, hFc Tag with the EC50 of 10.5ng/ml determined by ELISA (QC Test).
Immobilized Human CD20 VLP at 5μg/ml (100μl/well) on the plate. Dose response curve for Obinutuzumab, hFc Tag with the EC50 of 1.7ng/ml determined by ELISA.
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
MS4A1; CD20; MS4A-1; B1; Bp35; CD20 receptor; CD20S7; CVID5; LEU-16; Ly-44; MS4A2; S7
(1)Ma D , Mcdevitt M R , Barendswaard E , et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies[J]. Leukemia, 2002, 16(1):60-66. (2)Jager U , Fridrik M , Zeitlinger M , et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response[J]. Haematologica, 2012, 97(9):1431-1438.
